



## **ADDOS: The Role of Incentives\***

M. Ndomondo-Sigonda,<sup>1</sup> O. Kowero,<sup>1</sup> E. Alphonse,<sup>1</sup> Y. Hebron,<sup>1</sup> M. Kinyawa,<sup>2</sup> E. Mauga,<sup>2</sup>  
M. Smith,<sup>3</sup> R. Mbwasia,<sup>4</sup> R. Shirima,<sup>4</sup> N. Heltzer,<sup>4</sup> and M. Clark<sup>4</sup>

<sup>1</sup>Tanzania Food and Drugs Authority, Tanzania

<sup>2</sup>Muhimbili University College of Health Sciences, Tanzania

<sup>3</sup>Summa Foundation

<sup>4</sup>MSH/SEAM

To encourage DLDB owners and others to open ADDOs and maintain the required standards, an array of incentives to stimulate business growth and development have been developed. Discussions with groups of DLDB owners and other stakeholders suggested that the most powerful incentives would be: (1) an expanded drug list; (2) various economic enhancements; and (3) marketing and promotion campaigns to support and expand the ADDO markets. Here, we look at economic incentives, including the legal right to sell a limited range of prescription drugs; dispensing and business skills training; access to microfinancing; simplification of tax and business license fee liabilities; and links to health financing initiatives.

---

\* Poster originally displayed at the SEAM Conference 2003.